LEAP2 on Postprandial Glucose Metabolism and Food Intake n Obese Males

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study aims to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in obese volunteers. The overall objective is to investigate the physiological importance of LEAP-2 in obese subjects.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen

Criteria

Inclusion Criteria:

• Caucasian men

• Age between 18 and 25 years

• Body mass index between 30-50 kg/m2

• Informed consent

Exclusion Criteria:

• Anaemia (haemoglobin below normal range)

• Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) >2 times normal values) or history of hepatobiliary and/or gastrointestinal disorder(s)

• Nephropathy (serum creatinine above normal range and/or albuminuria)

• Allergy or intolerance to ingredients included in the standardised meals

• First-degree relatives with diabetes and/or glycated haemoglobin (HbA1c) >48 mmol/mol

• Regular tobacco smoking or use of other nicotine-containing products

• Any ongoing medication that the investigator evaluates would interfere with trial participation.

• Any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses